

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C07K 14/00</b>		A2	(11) International Publication Number: <b>WO 98/42737</b> (43) International Publication Date: 1 October 1998 (01.10.98)
(21) International Application Number: PCT/IB98/00415		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 20 March 1998 (20.03.98)			
(30) Priority Data: 120503 20 March 1997 (20.03.97) IL		Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(71) Applicant (for all designated States except US): HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT COMPANY LTD. [IL/IL]; P.O. Box 12000, Kiryat Hadassah, 91120 Jerusalem (IL).			
(72) Inventor; and			
(75) Inventor/Applicant (for US only): NAPARSTEK, Yaakov [IL/IL]; Davidson Street 17, P.O. Box 12047, 93706 Jerusalem (IL).			
(74) Agents: SHIRAN, Rinat et al.; Teva Pharmaceutical Industries Ltd., Patent Dept., P.O. Box 3190, 49131 Petah Tiqva (IL).			

**(54) Title:** PEPTIDES FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS**(57) Abstract**

A method is disclosed for treating systemic lupus erythematosus in a mammalian subject, comprising administering to said subject an effective dose of at least one laminin peptide, or an analog or a derivative thereof. In one exemplary embodiment, the laminin peptide is selected from the group consisting of R38, and claimed R38 analogs and derivatives thereof including 5200, 5104, 5105, 5106, 5107, 5108, 5109, and 5110. The laminin peptides of the present invention may be prepared by known chemical synthetic methods or by biotechnological methods. Assays useful for the diagnosis of and following pathological activity course of systemic lupus erythematosus in patients suffering therefrom.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

PEPTIDES FOR THE TREATMENT OF  
SYSTEMIC LUPUS ERYTHEMATOSUS

FIELD OF THE INVENTION

5

This invention relates to the use of laminin peptides and laminin derivatives, including R38 peptide and related analogs for the treatment and detection of systemic lupus erythematosus.

10    BACKGROUND OF THE INVENTION

Systemic lupus erythematosus (SLE) is an autoimmune disease involving multiple organs. Through the involvement of the kidneys in the autoimmune inflammatory process, lupus glomerulonephritis is a major cause of morbidity and mortality in this 15 disease (Alarcon-Segovia D. In: Primer on the Rheumatic diseases. Ed. Schumacher H.R. Arthritis Foundation, Atlanta, Georgia, (1988) pp. 96-100).

Serologically, the disease is characterized by the occurrence of a variety of autoantibodies in the serum, of which the most prominent are the anti-DNA auto 20 antibodies (Naparstek Y et al Annu. Rev. Immunol. (1993) 11 79-104). Although low titers of anti-DNA antibodies may occur in various inflammatory and autoimmune diseases, high levels are found mainly in SLE, and the combination of high anti-DNA antibodies with low complement levels is virtually diagnostic of SLE (Wallace D.J. et al In: Dubois' Lupus erythematosus. Lea and Febiger, Philadelphia, 1993).

25

The binding of immunoglobulins to the glomerular basement membrane (GBM) has been shown by the staining of kidneys derived from lupus patients or lupus strains of mice (Wallace D.J. et al *supra*). It has also been shown that anti-DNA antibodies eluted from the kidneys of a lupus patient as well as from MRL/1pr/1pr mice cross 30 react with sulfated glycosaminoglycans whereas the serum anti-DNA antibodies do not show this cross reactivity (Naparstek Y et al Arthritis Rheum. (1990) 33 1554-

1559). These results have suggested that extracellular matrix (ECM) play a role in pathogenesis of lupus as the target for the nephritogenic autoantibodies.

5 Termmat R.M. et al J. Autoimmun. (1990) 3 531-545, discloses the cross reaction of components of the ECM, like laminin and heparin with murine monoclonal anti-DNA antibodies.

10 EP Patent Application EP 670,495 discloses the presence of anti-ECM antibodies in the urine of patients with active lupus. Furthermore this patent application discloses the cross reaction of these antibodies with a 200 kDa laminin component of the ECM, and an assay for SLE based on the detection of these anti ECM/laminin antibodies in urine.

15 R38 is a peptide sequence isolated from the C-terminal region of the mouse laminin  $\alpha$  chain (residues 2890-2910 according to Skubitz et al., J. Cell Biol (1991) 115 1137-1148, or residues 2851-2871 according to Sasaki M. et al., J. Biol. Chem. (1988) 263, 16,536-16,544). It is located at the junction of the globular domains of the fourth and fifth loops (peptide GD-2 in Skubitz et al. J Cell Biol (1991) 115 1137-1148) and is comprised of the following amino-acid sequence:

20

KEGYKVRLDLNITLFRTTSK

25 Current SLE therapy is limited to corticosteroids which suppress the over-reactive immune system. This therapy is not specific and its inevitable side effects may themselves be fatal. Furthermore, immunosuppressive therapy is complicated and its initiation is based on a combination of clinical symptoms, blood serological tests and kidney biopsy. There is therefore a need for a more specific therapy for SLE that will not be associated with the side effects of the immunosuppressive agents as well as a more specific and less invasive assay for the evaluation of disease activity. Indeed a 30 recent review (The Lancet (1995) 310 1257-1261) stated that blood tests though useful in confirming diagnosis of SLE are "less useful in monitoring disease activity."

None of the above mentioned references disclose the treatment of systemic lupus erythematosus by the administration of the R38 peptide or analogs thereof. Moreover none of the above mentioned references disclose the use of R38 peptide in a diagnostic test for the disease or in monitoring disease activity. The contents of all 5 these patents and all literature references referred to above are hereby incorporated by reference in their entirety.

#### SUMMARY OF THE INVENTION

10 It is therefore an object of the present invention to provide a method for treating systemic lupus erythematosus comprising the administration of laminin peptides.

Another object of the present invention is to disclose R38' and other novel analogs and derivatives of R38 peptide, the administration of which comprises a method for 15 treating systemic lupus erythematosus.

A further object of the present invention is to provide a diagnostic test for the disease by using the R38 peptide, R38' peptide and other structurally related analogs and derivatives thereof.

20 The invention also relates to pharmaceutical compositions comprising the R38 peptide, R38' peptide and other novel analogs and derivatives of R38 peptide, or pharmaceutically acceptable salts thereof for use in the treatment of SLE.

25 As used herein the term "R38 peptide" is used to include the R38 peptide itself, analogs, derivative and fragments thereof that retain the activity of the complete peptide. The term analogs is intended to include variants on the peptide molecule brought about by, for example, homologous substitution of individual or several amino acid residues. The term derivative is used to include minor chemical changes 30 that may be made to R38 itself or analogs thereof that maintain the biological activity of R38 and similarly the term "fragments" is used to include shortened molecules of R38.

**BRIEF DESCRIPTION OF THE FIGURES**

Figure 1 shows the direct binding of C72 murine anti-DNA antibody to laminin peptides;

Figure 2 shows the inhibition by R38, 5200, DNA, DNase and heparin of the binding of C72 to the R38 analog 5200 (sometimes referred to herein as R38');

Figures 3 and 4 show the binding of the human lupus monoclonal anti-DNA antibodies (DIL6 and B3) to laminin peptides and derivatives thereof;

Figures 5,6 and 7 show the correlation between lupus activity score and urinary anti-R38 level in three lupus patients;

Figure 8 shows the effect of 5200 (R38') treatment on prolongation of survival of lupus mice;

Figure 9 shows the effect of R38 (also referred to herein as 5100) treatment on prolongation of survival of lupus mice; and

Figure 10 shows the inhibition of C72 binding to R38 (5100) by DNA and by R38 analogs.

**25 DESCRIPTION OF THE PREFERRED EMBODIMENTS**

Accordingly the present invention relates to the use of laminin peptides for the treatment of systemic lupus erythematosus.

The present invention is based on the observation that R38 peptide, which is a peptide derived from the C-terminal region of the mouse laminin  $\alpha$  chain, is recognized by pathogenic lupus antibodies and may therefore possess therapeutic potential in the

treatment of systemic lupus erythematosus by competing with the binding to the lupus antibodies.

Furthermore the present invention relates to the use of a mixture of at least two or  
5 more different peptides derived from laminin for the treatment of systemic lupus erythematosus. In a preferred embodiment, at least one of the peptides is R38 or an analog thereof.

The invention also relates to a method of monitoring disease activity of patients  
10 suffering from SLE comprising detecting the ability of the antibodies in the urine to bind to the R38 component of the laminin. This binding can have a direct correlation to disease activity evaluated by a combination of various laboratory parameters.

An increase in the amount of antibodies binding to R38 may indicate an approaching  
15 active phase of the disease and a declining level of antibodies, an approaching remission. Therefore, this method provides an assay for detecting changes in the level of laminin-specific antibodies and may enable the initiation of therapy prior to the onset of an active phase of the disease.

20 This method also provides an easy assay that can be used by the patients themselves as it is performed using urine and does not require venipuncture. It may be used as a diagnostic assay, a routine assay for evaluation of disease activity, for early identification of disease exacerbation and for early therapeutic intervention in lupus nephritis.

25 The R38 peptide or analogs, fragment or derivatives thereof may be used in such an assay using the methods described in EP 670,495. Thus, the R38 peptide may be bound to a solid phase and incubated with the urine from a patient. If the patient is suspected of suffering from SLE, suffering from SLE or is approaching an active  
30 phase of the disease, the level of R38-binding antibodies in the urine will increase.

- Detection of R38-binding antibodies may be undertaken by any method known by one skilled in the art. Examples of such methods of detection include ELISA and variations thereon, chemiluminescent techniques, etc. The actual method of detection is not crucial to the success of the assay. The level of R38-binding antibodies  
5 observed may then be compared to values observed in a control group. The control group may consist of healthy volunteers, or the patient may act as an internal control i.e. the observed value is compared to an earlier value from the same patient. In this manner a profile of the patient's disease state may be compiled and used as an indicator of further active phases or remission states of the disease.
- 10 Pharmaceutically acceptable salts of the R38 peptide include both salts of the carboxy groups and the acid addition salts of the amino groups of the peptide molecule. Salts of the carboxy groups may be formed by methods known in the art and include inorganic salts such as sodium, calcium, ammonium, ferric or zinc salts and the like  
15 and salts with organic bases such as those formed with amines such as triethanolamine, arginine or lysine, piperidine, procaine and the like. Acid addition salts include salts with mineral acids such as hydrochloric acid and sulphuric acid and salts of organic acids such as acetic acid or oxalic acid.
- 20 The pharmaceutical composition may contain laminin peptides such as the R38 peptide as unique peptides or in polymerized or conjugated forms attached to macromolecular carriers or polymers. The composition may optionally contain pharmaceutically acceptable excipients. In an alternative embodiment the composition may contain the R38 peptide alone.
- 25 The route of administration may include oral, intra-venous, intra-peritoneal, intra-muscular, subcutaneous, intra-articular, intra-nasal, intra-thecal, intra-dermal, trans-dermal or by inhalation.
- 30 An effective dose of the R38 peptide for use in treating SLE may be from about 1 $\mu$ g to 100mg/kg body weight, per single administration, which may be easily determined

by one skilled in the art. The dosage may depend upon the age, sex, health and weight of the recipient, kind of concurrent therapy, if any, and frequency of treatment.

### EXAMPLES

5

#### GENERAL

##### The Peptides

Peptides R26, R28, R30, R31, R35, R37, and R38 (also referred hereinafter as "5100") derived from the C-terminal of mouse laminin  $\alpha$  chain, and the R18 peptide derived from the N-terminal of mouse laminin  $\alpha$  chain were tested. The peptides are 17-22 -mer synthetic peptides, and were prepared by the F-moc technique (Carpino LA & Han GY (1972) J Org Chem 37 3404). These peptides could also be produced by methods well known to one skilled in the art of biotechnology. For example, using a nucleic acid selected from the group including DNA, RNA, cDNA, genomic, synthetic DNA, mRNA, total RNA, hnRNA, synthetic RNA, the desired peptides may be produced in live cell cultures and harvested.

10

The sequence of the peptides is presented in the Table 1:

15

Table 1: Laminin Derived Peptides.

PEPTIDES	RESIDUES (*)	SEQUENCE
R18	42-63	RPVRHAQCRVCDGNSTNPRERH
R26	2443-2463	KNLEISRSTFDLLRNSYGVRK
R35	2547-2565	TSLRKALLHAPTGSYSDGQ
R37	2615-2631	KATPMLKMRRTSFHGCIK
R28	2779-2795	DGKWHTVKTEYIKRKAF
R38	2890-2910	KEGYKVRLDLNITLEFRTTSK
R30	3011-3032	KQNCLSSRASFRGCVRNLRSLR

(\*) Residue designations per Skubitz supra.

Other laminin peptides used for comparative purposes in the Examples include AS31 (comprising the residues YIGSR), AC15 and F9 (other laminin peptides) and R27 a peptide from the 4th loop of the globular region of the laminin  $\alpha$  chain.

- 5 Additional peptides which are fragments of, or analogs closely derived from R38 have been constructed and are presented in Table 2 hereinbelow. Peptides 5200 and 5101-5111 disclosed in Table 2 were prepared in the same manner as the peptides of Table 1 hereinabove. The Table 2 peptides comprise R38 (5100), human R38 (5300),  
 10 fragments of R38, a fragment 5111 derived from 5300 or analogs of R38 wherein one or more point substitutions were made according to techniques which are well known to one skilled in the art. These peptides were constructed to investigate, among other things, the effect on anti-DNA antibody binding activity caused by changing the net charge of the R38 peptide.

15

TABLE 2 - Synthetic Peptides Analogous To Mouse R38 Peptide

Peptide #	AMINO ACID SEQUENCE	DESCRIPTION	Net Charge
5100	KEGYKVRDLNITLEFRTTSK	Mouse R38	+2
5200	KEGYKVRDLNITLEFRTTSK	Mouse R38 analog	+2
5300	KEGYKVQSDVNITLEFRTSSQ	Human R38	0
5101	KEGYKVRDLNITLEF	Res. 1-16 of 5100	0
5102	VRDLNITLEF	Res. 6-17 of 5100	0
5103	LDLNITLEFRTTSK	Res. 8-21 of 5100	0
5104	AEGYAVALDLNITLEFATTSA	Ala subst. of 5100 at all positive a.a.	-3
5105	KEGYKVELDLNITLEFETTSK	charge subst. to neg. at 5100 a.a. 7 and 17	-2
5106	KEGYKVELDLNITLEFRTTSK	charge subst. to neg. at 5100 a.a. 7	0
5107	KEGYKVRDLNITLEFETTSK	charge subst. to neg. at 5100 a.a. 17	0
5108	KAGYKVRALNLITLAFRTTSK	Ala subst. of 5100 at all negative a.a.	+5
5109	KEGYKVRALNLITLEFRTTSK	Ala subst. of 5100 a.a. 9	+3
5110	KEGYKVRDLNLITLAFRTTSK	Ala subst. of 5100 a.a. 15	+3
5111	VQSDVNITLEFR	Res. 8-17 of 5300	-1

a.a. Amino Acid

Monoclonal Antibodies

The C72 murine anti-DNA antibody has been derived from (NZBxNZW)F1 lupus mice by the hybridoma technique as described in Eilat D. et al J. Immunol. (1991) 147 5 361-368. The monoclonal anti-DNA antibodies DIL6 and B3 were derived from lupus patients by hybridoma technique as described in Ehrenstein M.R. et al J. Clin. Invest. (1994) 93 1787-1799 and Ehrenstein M.R. et al Kidney Inter. (1995) 48 705-711.

It should be understood that the following description contemplates use of antibodies 10 specific to the laminins and to the peptides disclosed herein. Methods for producing peptides specific to the laminin peptides and to R38 and its analogs and derivatives are well known to one skilled in the art. In this regard, specific reference may be had to the text "Antibodies, A Laboratory Manual," Ed Harlow and David Lane, Cold Spring Harbor Publishing, 1988, the contents of which are incorporated herein by 15 reference. This reference discloses methods which may be used for obtaining monospecific antibodies, i.e., monoclonal antibodies and polyclonal antibodies directed against laminin peptides.

Anti-Peptide (Direct Binding) ELISA:

20 Wells were coated with 10 µg/ml of the peptides, blocked with 1% BSA (bovine serum albumin) in PBS (pH 7.4), reacted with appropriately diluted serum or urine samples or monoclonal antibodies, incubated with anti-human or anti-mouse immunoglobulin enzyme conjugated to alkaline phosphatase and detected by addition 25 of substrate (Sigma 100 Phosphatase Substrate Tablets) and color development using an Organon Teknika Microwell System spectrometer at wavelength of 405nm.

Competitive Inhibition Assays:

30 In competitive inhibition assays, the antibodies were incubated with various concentrations of the inhibitor (for example: peptide, DNA, heparin) or with DNase

for 45 minutes at room temperature and the remaining binding was then evaluated by ELISA as described heretofore.

% inhibition was computed as:

$$\frac{\text{O.D. binding without inhibitor} - \text{O.D. binding with inhibitor}}{\text{O.D. binding without inhibitor}} \times 100 = \% \text{ inhibition}$$

5

#### EXAMPLE 1: Binding of Laminin Peptides To SLE Antibodies

##### A: Murine SLE antibodies bind to C terminal peptides of laminin $\alpha$ chain.

10

The interaction of the C72 murine anti-DNA antibody with laminin peptides was analyzed by ELISA as described above. The C72 conditioned medium was diluted in PBS in various dilutions. The results are summarized in Figure 1 which shows the binding of C72 murine anti-DNA antibody to the 5200, R37, and R30 peptides, but not to R28 or R18 peptides of the laminin  $\alpha$  chain. Control murine antibody, the anti-HEL Hy5 did not bind to the 5200 peptide (data not shown).

##### B: Inhibition of the binding of C72 to 5200 is inhibited by DNA and Heparin

20

The binding of C72 to 5200 was tested before and after incubation with 5200, R38, R18, Heparin, DNA and DNase. The results are summarized in Figure 2 which shows the inhibition of the binding of C72 to 5200 by the R38 or 5200 peptides of the present invention, by DNA and by heparin, but not by a control peptide or treatment with DNase. The percent inhibition is the percent reduction of the O.D. after 25 incubation with the inhibiting agent.

#### EXAMPLE 2: Polyclonal Murine Antibodies Bind To The 5200 Peptide

Analysis of the interaction of MRL/1pr/1pr urine antibodies with the 5200 peptide by 30 a direct binding ELISA revealed specific binding. Thus, pooled urine from at least 5

mice (either MRL/lpr/lpr or control mice, e.g. BALB/c) was added to wells coated with R38' (5200), R18 or DNA as described above and bound 5200 assayed by ELISA.

### 5 Binding Of Murine Urinary Immunoglobulins To 5200

Each group is comprised of pooled urine.

MICE	ANTIGEN		
	DNA	5200	R18
BALB/c	U.D.	U.D.	U.D.
MRL/lpr/lpr	U.D.	0.26 (*)	U.D.

U.D. - Undetected

(\*) O.D. at 405 nm.

10

### EXAMPLE 3: Human Monoclonal Lupus Antibodies Bind The 5200 Peptide

The human monoclonal anti-DNA antibodies DIL 6 and B3 were derived from lupus patients by the hybridoma technique. As shown in Figures 3 and 4 these antibodies were found to bind to the 5200 peptide but not to other laminin peptides tested. In Figures 3 and 4, the peptides are referred to as denoted above or as follows; AS30 is R27, AS19 is R35, AS35 is R26, AS17 is R28 and AS6 is R18.

20

### EXAMPLE 4: Effect Of R38 (5100) & R38' On The Clinical Course Of Murine SLE

To test whether R38 peptides can affect the course of SLE we have tested their effect on MRL/lpr/lpr mice disease. 60 $\mu$ g of 5200 (R38' alone or in peptide combinations, 30 $\mu$ g of each) in 0.1ml PBS, was injected i.p. to 6 week old female MRL/lpr/lpr mice once a week for 16 weeks and the mice were evaluated for survival (Fig. 8), and for renal histology.

50 $\mu$ g of 5100 (R38) or 5300 (human R38) in 0.1ml PBS, was injected i.p. to 6 week old MRL/1pr/1pr mice three times a week and the mice were evaluated for survival (Figure 9), and for renal histology. Control mice received 0.1ml phosphate buffer solution. Each test and control group contained 12 - 15 mice.

5

The survival of MRL/1pr/1pr mice treated with 5100, 5200 or 5300 was compared to that of PBS treated mice. As shown in Figures 8 and 9, the survival of mice treated with 5100 or 5200 was significantly higher than that of control mice. In Figures 8 and 9 the time in days shown on the x axis relates to the age of the mice.

10 Two mice in each group were sacrificed after 5 months and their kidneys evaluated by light microscopy. The kidneys from the control mice showed severe diffuse proliferative glomerulonephritis with crescents and sclerosis whereas the 5100 or 5200 treated mice showed mild proliferative changes with no crescents and no sclerosis.

15

EXAMPLE 5 -Analysis of the Correlation between Anti- R38 Antibodies and Disease Activity

Urine from lupus patients with and without renal disease in active and inactive state  
20 were collected repeatedly and tested for presence of anti-R38 antibodies by ELISA. Activity of the disease was evaluated also by accepted clinical and serological parameters (Lockshin M.D. et al Am. J. Med. (1984) 77 893-898) and their correlation with anti-R38 levels was compared.

25 103 urine samples of 37 SLE patients were tested for anti-R38 activity by ELISA as described above. 23 of the samples were from patients without renal disease and 80 samples from patients with renal disease. A further 12 samples from patients with renal disease not relates to SLE were also included

The following results were obtained:

SLE	Present	Present	Absent
Renal Disease	Absent	Present	Present
No. Samples	23	80	12
Urine anti-R38	$0.035 \pm 0.003$	$0.229 \pm 0.03^*$	$0.07 \pm 0.01$
O.D. (Mean+S.E.)			

\* $p < 0.001$

Positivity of the samples in those patients with renal disease usually correlated with active disease according to an activity score that includes 19 clinical and laboratory parameters (Lockshin M.D. et al *supra*). These parameters included assessment of the presence/absence/condition of the following clinical criteria alopecia, rash, fever, serositis, arthralgia/arthritis, mucosal ulcers, neurological events, malaise, fundi changes, nodes, spleen and the following blood tests including ESR (erythrocyte sedimentation rate), anti DNA antibodies, complement (U/ml), creatinine, haemoglobin (g/dl), PLT platelets ( $/mm^3$ ) or urinalysis. The assessment of these parameters is measured as described in Lockshin *supra*. The overall percentage given reflects only the assessed parameters.

In some patients urine samples were tested in more than one occasion and a good correlation between the clinical activity and the level of anti R38 binding were observed. Three representative examples from three different lupus patients are shown in Figures 5,6 and 7 where the x-axis shows the No. of the hospital visit and the y-axis, the observed binding (OD at 405nm) or percentage of the activity score described above. As can be seen from these Figures, the assay using the R38 peptide provides a reliable method of monitoring disease activity.

EXAMPLE 6 - Analysis of the Correlation Between anti-5200 (R38') Antibodies and Disease Activity.

In an additional experiment, 178 urine samples from lupus patients, 24 with and 22 without renal disease in active and inactive state were collected and tested for

presence of anti-5200 antibodies by ELISA as described above. The following results were obtained:

Renal Disease	Absent	Present
No. Samples	46	132
Urine anti-5200	$0.05 \pm 0.005$	$0.335 \pm 0.035^*$
O.D. (Mean+S.E.)		

\* $p < 0.001$

5    EXAMPLE 7 - Analysis of the Correlation Between anti-5100 (R38) Antibodies and Disease Activity.

45 urine samples from 21 lupus patients, some with and some without renal disease in active and inactive state were collected and tested for presence of anti-5100 antibodies  
10    by direct ELISA as described above.

The following results were obtained:

Renal Disease	Absent	Present
No. Samples	6	39
Urine anti-5100	$0.058 \pm 0.006$	$0.376 \pm 0.05^*$
O.D. (Mean+S.E.)		

\* $p < 0.03$

15    EXAMPLE 8 - Analysis of the Correlation Between anti-5200 (R38') Antibodies and Disease Activity.

52 urine samples from 21 lupus patients, with and without renal disease in active and inactive state were collected and tested for presence of anti-5200 antibodies by ELISA  
20    as described above.

The following results were obtained:

Renal Disease	Absent	Present
No. Samples	6	46
Urine anti-5200	0.052±0.03	0.431±0.09
O.D. (Mean+S.E.)		

**EXAMPLE 9 - Analysis of the Correlation Between Anti-5108, 5101, 5109 and**

**5   5110 - Antibodies and Disease Activity**

24 urine samples from some of the lupus patients of Examples 7 and 8, 2 with and 22 without renal disease in active and inactive state were collected and tested for binding to 5108 peptides by ELISA as described above.

10

The following results were obtained:

Renal Disease	Absent	Present
No. Samples	2	22
Urine anti-5108	0.064±0.05	0.672±0.1
O.D. (Mean+S.E.)		

Similar results were observed for binding of peptides 5101, 5109 and 5110.

15

**EXAMPLE 10 - Direct Binding Of C72 And B3 To R38 And Analog Peptides**

The peptides of the present invention were tested for their ability to bind directly with C72 murine anti-DNA antibodies and B3 human anti-DNA antibodies according to 20 the method described hereinabove. The results of the direct binding study are reported in Table 3:

Table 3 - Direct Binding Of C72 And B3 To R38 And Analog Peptides

Peptide #	C72 Binding <sup>†</sup>	B3 Binding <sup>‡</sup>
5100	2.57	0.9
5200	1.6	0.25
5300	0.03	0.03
5101	1.11	0.1
5102	0.1	0.02
5103	0.03	0.02
5104	0.06	0.02
5105	0.07	0.02
5106	1.9	0.16
5107	0.05	0.01
5108	2.75	1.93
5109	2.72	1.94
5110	2.8	1.83
5111	0.01	0.01
R18	0.01	NT <sup>*</sup>
R28	0.01	NT
R30	0.75	NT
R37	1.8	NT

<sup>\*</sup>NT - Not Tested<sup>†</sup> - O.D. in a direct binding ELISA test after one (1) hour.5    <sup>‡</sup> - O.D. in a direct binding ELISA test after two (2) hours.

**EXAMPLE 11: Competitive Inhibition Of C72 Binding To R38 With Analog Peptides**

10

A competitive inhibition study compared how each of the peptides competes with R38 (5100) for binding to the C72 anti-DNA antibody. Conducted according to the methods described hereinabove, the results of the study are disclosed in Table 4 below and are further elucidated by reference to Fig. 10.

Table 4: Inhibition of C72 Binding to R38

Peptide #	50% inhibition of C72 binding to mouse R38 (5100) in µg/ml*
5100	10
5200	10
5300	85
5101	5
5102	30
5103	NI**
5104	NI
5105	NI
5106	2.5
5107	85
5108	2
5109	0.7
5110	0.7
5111	NI

\* - Concentration of competitive inhibitor which resulted in 50% inhibition of the binding of C72 anti-DNA antibody to peptide 5100 (R38) in an ELISA test.

\*\*NI - No Inhibition

5

It should be understood that the foregoing description and examples are merely illustrative and that many modifications and variations may be made thereto by one skilled in art without departing from the scope and spirit of the invention as claimed hereinbelow.

CLAIMS

1. A method for treating systemic lupus erythematosus in a mammalian subject, comprising administering to said subject an effective dose of at least one laminin peptide, or an analog or a derivative thereof.  
5
2. The method according to claim 1, wherein said at least one laminin peptide is selected from the group consisting of R38, and R38 analogs and derivatives thereof including 5200, 5104, 5105, 5106, 5107, 5108, 5109, and 5110.
- 10 3. The use of at least one laminin peptide for making a medicine suitable for administration in a mammalian subject suffering from systemic lupus erythematosus.
- 15 4. The use according to claim 3, wherein said at least one laminin peptide is selected from the group consisting of R38, and R38 analogs and derivatives thereof including 5200, 5104, 5105, 5106, 5107, 5108, 5109, and 5110.
- 20 5. A pharmaceutical composition for the treatment of systemic lupus erythematosus comprising an affective amount of at least one laminin derived peptide and a pharmaceutical acceptable carrier.
- 25 6. A pharmaceutical composition according to claim 5 wherein said at least one laminin peptide is selected from the group consisting of R38, and R38 analogs and derivatives thereof including 5200, 5104, 5105, 5106, 5107, 5108, 5109, and 5110.

25

7. A method of monitoring the activity of systemic lupus erythematosus comprising:

- (a) obtaining a sample of urine from the patient;
- (b) detecting R38-binding antibodies in said sample, wherein said antibodies specifically bind with an R38 antigen; and
- (c) comparing the amount of said R38-binding antibodies to a control value.

8. A method according to claim 7, wherein the control value comprises prior results from said patient.

9. A method of monitoring the progress of SLE in a patient comprising

- (a) incubating a urine sample from said patient with a R38 peptide or fragment thereof, said peptide being linked to a solid phase;
- (b) detecting R38 antibodies in said sample, wherein said antibodies specifically bind with an R38 antigen; and
- (c) comparing the amount of bound R38 peptide to a control value.

10. The method according to claim 7 to 9, wherein said antigen is directly or indirectly immobilized upon a solid phase material.

11. A peptide selected from the group having the amino acid sequences:  
KEGYKVRLDLNTTLEFRTTSK, AEGYAVALDLNITLEFATTSA,  
KEGYKVELDLNITLEFETTSK, KEGYKVELDLNITLEFRTTSK,  
25 KEGYKVRLDLNITLEFETTSK, KAGYKVRLALNITLAFRTTSK,  
KEGYKVRLALNITLEFRTTSK, and KEGYKVRLDLNITLAFRTTSK.

12. A nucleic acid sequence encoding a peptide having an amino acid sequence selected from the group consisting of:  
30 KEGYKVRLDLNTTLEFRTTSK, AEGYAVALDLNITLEFATTSA,  
KEGYKVELDLNITLEFETTSK, KEGYKVELDLNITLEFRTTSK,  
KEGYKVRLDLNITLEFETTSK, KAGYKVRLALNITLAFRTTSK,  
KEGYKVRLALNITLEFRTTSK, and KEGYKVRLDLNITLAFRTTSK.

13. The nucleic acid sequence of claim 12; wherein said nucleic acid is selected from the group consisting of DNA, RNA, cDNA, genomic DNA, synthetic DNA, mRNA, total RNA, and hnRNA.

5 14. A monospecific antibody directed against a laminin peptide or analog or derivative thereof.

10 15. The monospecific antibody of claim 14 wherein said laminin peptide, analog or derivative thereof is selected from the group consisting of R38, , and R38 analogs and derivatives thereof including 5200, 5104, 5105, 5106, 5107, 5108, 5109, and 5110.

16. A polyclonal antibody directed against a laminin peptide or analog or derivative thereof .

15

17. The polyclonal antibody of claim 16 wherein said laminin peptide, analog or derivative thereof is selected from the group consisting of R38, , and R38 analogs and derivatives thereof including 5200, 5104, 5105, 5106, 5107, 5108, 5109, and 5110.

20 18. A monoclonal antibody directed against a laminin peptide or analog or derivative thereof .

25 19. The monoclonal antibody of claim 18 wherein said laminin peptide, analog or derivative thereof is selected from the group consisting of R38, , and R38 analogs and derivatives thereof including 5200, 5104, 5105, 5106, 5107, 5108, 5109, and 5110.

20. A nucleic acid encoding a laminin derived peptide, said laminin derived peptide having 50% binding inhibitory activity when competing with R38 in binding to C72 anti-DNA antibody at a dose no greater than 85 µg/ml.

30

21. A nucleic acid encoding a laminin derived peptide, said laminin derived peptide having direct binding activity with C72 murine anti-DNA antibody as measured by ELISA of at least .75 O.D. after one hour.
- 5 22. A nucleic acid encoding a laminin derived peptide, said laminin derived peptide having direct binding activity with B3 human anti-DNA antibody as measured by ELISA of at least .1 O.D. after two hours.

1/7




Fig.1

2/7




Fig.2

3/7




Fig.3




Fig.4

4/7




Fig.5




Fig.6

5/7




Fig.7

6/7




Fig.8





Fig.9

7/7

Fig.10



PCT



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12N 15/12, C07K 14/78, A61K 38/39, G01N 33/68, C07K 16/28		A3	(11) International Publication Number: WO 98/42737 (43) International Publication Date: 1 October 1998 (01.10.98)
(21) International Application Number: PCT/IB98/00415		(61) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 20 March 1998 (20.03.98)			
(30) Priority Data: 120503 20 March 1997 (20.03.97) IL			
(71) Applicant (for all designated States except US): HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT COMPANY LTD. [IL/IL]; P.O. Box 12000, Kiryat Hadassah, 91120 Jerusalem (IL).		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(72) Inventor; and			
(75) Inventor/Applicant (for US only): NAPARSTEK, Yaakov [IL/IL]; Davidson Street 17, P.O. Box 12047, 93706 Jerusalem (IL).			
(74) Agents: SHIRAN, Rinat et al.; Teva Pharmaceutical Industries Ltd., Patent Dept., P.O. Box 3190, 49131 Petah Tiqva (IL).		(88) Date of publication of the international search report: 5 November 1998 (05.11.98)	

**(54) Title: PEPTIDES FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS**

### (57) Abstract

A method is disclosed for treating systemic lupus erythematosus in a mammalian subject, comprising administering to said subject an effective dose of at least one laminin peptide, or an analog or a derivative thereof. In one exemplary embodiment, the laminin peptide is selected from the group consisting of R38, and claimed R38 analogs and derivatives thereof including 5200, 5104, 5105, 5106, 5107, 5108, 5109, and 5110. The laminin peptides of the present invention may be prepared by known chemical synthetic methods or by biotechnological methods. Assays useful for the diagnosis of and following pathological activity course of systemic lupus erythematosus in patients suffering therefrom.

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

# INTERNATIONAL SEARCH REPORT

In International Application No  
IB 98/00415

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/12 C07K14/78 A61K38/39 G01N33/68 C07K16/28

According to International Patent Classification(IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 04926 A (UNIV VIRGINIA) 22 February 1996 see page 7, paragraph 2 see page 11, paragraph 2; claims; examples	1,5
A	EP 0 670 495 A (HADASIT MED RES SERVICE) 6 September 1995 see page 8, line 46 - line 50; claims; examples	1,7
P, A	EP 0 765 660 A (TAKEDA CHEMICAL INDUSTRIES LTD) 2 April 1997 see page 28, line 6 - line 30; claims	1,7
	---	-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

### \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

27 August 1998

14/09/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Fuhr, C

**INTERNATIONAL SEARCH REPORT**

International Application No

PCT/IB 98/00415

**C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	A. BEN-YAHUDA ET AL.: "The Urine of SLE Patients Contains Antibodies that Bind to the Laminin Component of the Extracellular Matrix" JOURNAL OF AUTOIMMUNITY, vol. 8, no. 2, 1995, pages 279-291, XP002075723 see page 286, paragraph 2 - page 290, paragraph 3 -----	1,7

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/IB 98/00415

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: 1 and 2  
because they relate to subject matter not required to be searched by this Authority, namely:  
**Remark:** Although claims 1 and 2  
are directed to a method of treatment of the human/animal  
body, the search has been carried out and based on the alleged  
effects of the compound/composition.
2.  Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:
3.  Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- The additional search fees were accompanied by the applicant's protest.  
 No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

IB 98/00415

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 9604926	A	22-02-1996	US	5493008 A	20-02-1996
			AU	3235895 A	07-03-1996
			CA	2196053 A	22-02-1996
			EP	0771210 A	07-05-1997
			JP	10504306 T	28-04-1998
EP 0670495	A	06-09-1995	JP	8035966 A	06-02-1996
			US	5789260 A	04-08-1998
EP 0765660	A	02-04-1997	CA	2186709 A	29-03-1997
			JP	9315975 A	09-12-1997